Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432037 | 1.00 | TACR1 (0.47) | TACR1F2HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL1433925 | 0.96 | XIAP (0.45) | TACR1F2HDAC1HDAC2HDAC3 | |
| SCHEMBL1433063 | 0.91 | HDAC1 (0.44) | TACR1F2HDAC1HDAC2HDAC3 | |
| SCHEMBL1431568 | 0.87 | TACR1 (0.44) | TACR1XIAPITGB1ITGA4MASP2 | |
| SCHEMBL1432028 | 0.87 | HDAC1 (0.40) | F2HDAC1HDAC2HDAC3XIAP | |
| SCHEMBL1432334 | 0.86 | F2 (0.46) | F2HDAC1HDAC2HDAC3XIAP | |
| SCHEMBL1432215 | 0.86 | TACR1 (0.45) | TACR1F2XIAPMASP2 | |
| SCHEMBL1432153 | 0.85 | TACR1 (0.43) | TACR1XIAPITGB1ITGA4MASP2 | |
| SCHEMBL1432977 | 0.84 | F2 (0.49) | F2ITGB1ITGA4 | |
| Hydrochloric Acid SCHEMBL3256738 | 0.84 | TACR1 (0.46) | TACR1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | TACR1 953/4885F2 1046/4885HDAC1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.